Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
about
Components of an anticancer diet: dietary recommendations, restrictions and supplements of the Bill Henderson ProtocolAntiangiogenic mechanisms and factors in breast cancer treatmentThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateToxin-based therapeutic approachesThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisG protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasisSomatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypesIncreased matrix metalloproteinase activation in esophageal squamous cell carcinomaAttenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic ratsMMP-9 expression varies according to molecular subtypes of breast cancer.A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.Engineering attenuated virulence of a Theileria annulata-infected macrophageReduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production.A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expressionStress hormone-mediated invasion of ovarian cancer cells.RSK1 activation promotes invasion in nodular melanoma.Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian CancerThe Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis.E6/E7 oncoproteins of high risk HPV-16 upregulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells.Flavokawain B induced cytotoxicity in two breast cancer cell lines, MCF-7 and MDA-MB231 and inhibited the metastatic potential of MDA-MB231 via the regulation of several tyrosine kinases In vitro.Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcomaDNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion.The influence of matrix metalloproteinase-2, -9, and -12 promoter polymorphisms on Iranian patients with oesophageal squamous cell carcinomaEngineering approaches for investigating tumor angiogenesis: exploiting the role of the extracellular matrixModulation of cancer traits by tumor suppressor microRNAs.Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.Role of metabolic modulator Bet-CA in altering mitochondrial hyperpolarization to suppress cancer associated angiogenesis and metastasis.Genetic alterations in pancreatic cancer.MMP-9 signaling in the left ventricle following myocardial infarction.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.In Vivo Angiogenic Capacity of Stem Cells from Human Exfoliated Deciduous Teeth with Human Umbilical Vein Endothelial Cells.Nanoparticle-mediated arresten gene inhibits neointimal formation of vein grafts: an experimental research.The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesisTumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis.Vascular permeability and drug delivery in cancers.Profiling serum HER-2/NEU in prostate cancer.Enzymatic aspects in ENT cancer-Matrix metalloproteinases.
P2860
Q24610181-7C52314E-69E1-497A-98BD-E59716E97DA1Q26751226-8949A5A2-2215-4C5F-A0F9-B16A60E5BE40Q27003050-6E0BFC69-B465-4DE0-AB93-7B04E07F9D13Q27013664-B4F00464-472D-4368-BC50-20476CA1F6E4Q28388257-7BD164B4-3365-4C8E-B7E7-1AA4CB2C7B42Q30413082-71A61331-80B5-4777-BA40-C82D18DAEF81Q30415151-5ACB9DF0-3A9F-40EF-87B9-A83F09820229Q33710260-6CA7AD6E-B094-41FB-8D49-B8B0272FEF0CQ33793466-D6F6A26F-E48A-460B-8E5A-24A8C9A0E65CQ34116451-A06039D2-32AD-449A-971E-634219BCC5A0Q34358400-DCB1695E-374B-4865-8ED5-44832278AC1BQ34464879-A1341098-DD3C-4362-9663-7FDE63A6330CQ34485591-B6CD858D-9A61-4B7D-BC47-EB413722BE13Q34654695-0A16A7C2-D696-4621-AF81-DEDC2074DBCCQ35120288-B8E3E471-F8DC-4EF8-847F-22D05FEF88B4Q35143744-E700584E-B788-433E-9029-5E50895ABF21Q35435361-0DA5BA27-55FC-418B-ADFC-F0FAC8ABDADCQ35563128-19D6ADDD-4EB6-435A-8EE2-91544C6CA2CEQ35749723-85D516B2-7E50-4143-8E86-A3E50CA93248Q35850001-760B2E43-E5C1-4624-89F3-C450C60E1891Q35854023-084B44FF-FCBA-407B-815F-A9DB89E99E8CQ35938289-B5630034-731C-4873-8887-D4BBF9455A30Q35958404-667CF448-98BF-4DD5-AF09-43D2FD4CA658Q36187532-4615BCA3-6535-4038-9149-DB64B5A9A90BQ36243972-3E574AC3-01AB-4A4C-8085-A2B2B6E6DD67Q36442261-AB31E564-A042-4309-A5A4-0A790DD77E79Q36590130-6674DC4F-505A-4300-8E91-1F88BD370F73Q36675764-26B36BC9-7AE3-4274-ABDC-7E010ED2F0E8Q36713661-3A254E0C-D23F-456D-BD27-C884F33CEA51Q36921331-18C4559E-AF26-4288-84D4-6E77FD40E0F1Q37139613-C34F7E90-3864-4F45-89C3-4992FA39586CQ37236103-E02B1975-68A3-4C31-9A43-6692CD0E02E2Q37251091-DC3BDAC5-1FF8-43ED-8C6A-C28622403355Q37446733-F5E3CBB1-79DF-42D5-9008-94AA86366A1EQ37528238-1B9388AB-123E-4351-8132-3F1BE1E1DE65Q37529387-4C845D87-557A-4FEB-8AF4-2E4F02CA6566Q37662196-802F330B-1C67-4E76-A8EF-E2DC27C46A81Q38130686-9E949AED-D451-4CFB-AD7A-DF4D4B5DFADAQ38174595-ABAEF599-155D-4598-A50F-A29E16F4EA35Q38269499-C8D1E1E9-285D-45A8-993C-34A56AC39580
P2860
Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@ast
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@en
type
label
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@ast
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@en
prefLabel
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@ast
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@en
P1476
Matrix metalloproteinases, ang ...... . Cancer Res., 9: 00-00, 2003.
@en
P2093
Joyce E Rundhaug
P304
P407
P577
2003-02-01T00:00:00Z